Clik here to view.
NeuroVia Initiates Phase 1/2 Trial of NV1205 for Treating Childhood Cerebral...
SAN FRANCISCO NeuroVia, Inc., a biopharmaceutical company focused on developing innovative therapies for rare, genetic neurological diseases, today announced the initiation of a Phase 1/2 clinical...
View ArticleClik here to view.
Dr. Reddy’s Laboratories Announces the Launch of Hervycta® (trastuzumab...
HYDERABAD, India Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY) announced today that it has launched Hervycta® (trastuzumab), a biosimilar of Roche’s Herceptin®, in India, indicated for...
View ArticleClik here to view.
OMRON’s First-Quarter Net Sales Climb 3.1%, to Record ¥209.8 Billion, Driven...
KYOTO, Japan OMRON Corporation today announced its consolidated operating results for the first quarter of fiscal 2018, ending June 30, 2018. Net sales increased 3.1%, to ¥209.8 billion, while gross...
View ArticleClik here to view.
Dr. Reddy’s Q1 FY19 Financial Results
HYDERABAD, India Dr. Reddy’s Laboratories Ltd. (BSE: 500124 | NSE: DRREDDY | NYSE: RDY) today announced its consolidated financial results for the quarter ended June 30, 2018 under International...
View ArticleClik here to view.
Pierre Fabre receives positive CHMP opinion for BRAFTOVI® (encorafenib) +...
CASTRES, France Pierre Fabre today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending approval of...
View ArticleClik here to view.
Clinical Innovations Accelerates Global Growth Strategy with Establishment of...
SALT LAKE CITY Clinical Innovations, one of the world’s leading medical device-makers dedicated to labor and delivery and neonatal intensive care, today announced the establishment of CI Medical...
View ArticleClik here to view.
武田薬品、ALUNBRIG®（ブリガチニブ）の第3相試験が主要評価項目を達成し、ALK阻害剤未治療の進行性ALK陽性NSCLC患者でクリゾチニブと比較して...
米マサチューセッツ州ケンブリッジ & 大阪 （ビジネスワイヤ） — 武田薬品工業株式会社（TSE: 4502）は本日、グローバルランダム化第3相ALTA-1L試験（ALK in Lung Cancer Trial of AP26113 in 1st...
View ArticleClik here to view.
武田宣布3期ALUNBRIG®...
马萨诸塞州剑桥和日本大阪 (美国商业资讯) — 武田药品工业株式会社(TSE: 4502)今天宣布，全球随机3期ALTA-1L（ALK in Lung Cancer Trial of AP26113 in 1st...
View ArticleClik here to view.
Astex Pharmaceuticals and Otsuka Announce Results of the Phase 3 ASTRAL-1...
PLEASANTON, Calif. & TOKYO Astex Pharmaceuticals, a member of the Otsuka group of companies, and Otsuka Pharmaceutical Co. Ltd., announce top-line results from the ASTRAL-1 study evaluating the...
View ArticleClik here to view.
Takeda Completes its Acquisition of TiGenix Following Expiration of the...
OSAKA, Japan & LEUVEN, Belgium Takeda Pharmaceutical Company Limited (TSE: 4502) (“Takeda”) and TiGenix NV (“TiGenix”) today announced that Takeda has acquired all outstanding ordinary shares...
View ArticleClik here to view.
Takeda Reports First Quarter FY2018 Results
OSAKA, Japan Takeda Pharmaceutical Company Limited (TOKYO:4502): Underlying Revenue growth +6.4% with growth in every region Underlying Revenue grew +6.4%, led by Takeda’s Growth Drivers...
View ArticleClik here to view.
2018年度第1四半期（4-6月期）の連結業績について
大阪 （ビジネスワイヤ） — 武田薬品工業株式会社 （東証：4502）： 実質的な売上収益は＋6.4％、すべての地域で増収 売上収益の実質的な成長は、タケダの成長ドライバー（消化器系疾患領域、オンコロジー、ニューロサイエンス、新興国事業）の＋11.8％の力強い伸長により、対前年同期＋6.4％、主力製品であるエンティビオ（＋34.1％）およびニンラーロ（＋43.3％）が大きく貢献...
View ArticleClik here to view.
MerLion Regains North American Rights to XTOROTM FDA-Approved Antibiotic for...
SINGAPORE MerLion Pharmaceuticals (MerLion), a pharmaceutical company focused on the advanced clinical development of its antibacterial drug finafloxacin, today announced that Novartis has made a...
View ArticleClik here to view.
Infraredx Announces Launch of Makoto™ Intravascular Imaging System and...
BURLINGTON, Mass. Infraredx, Inc., a pioneer in intravascular imaging for mapping coronary artery disease, today announced the Makoto™ Intravascular Imaging System, and accompanying Dualpro™...
View ArticleClik here to view.
CANbridge Life Sciences Appoints Chief Medical Officer
BEIJING CANbridge Life Sciences, a biopharmaceutical company developing Western drug candidates in China and North Asia, announced that it strengthened the executive management team with the...
View ArticleClik here to view.
武田公布2018财年第一季度业绩
日本大阪 (美国商业资讯)–武田药品工业株式会社(Takeda Pharmaceutical Company Limited, TOKYO:4502)： 基础营收增长+6.4%，各个地区均有增长 基础营收增长+6.4%，武田的增长引擎（胃肠药、肿瘤药、神经科药物和新兴市场）与前一年相比展现了强劲增长，增幅达到+11.8%。主要产品Entyvio (+34.1%)和Ninlaro...
View ArticleClik here to view.
Baxter Announces CE Mark and Regulatory Approval of New Evo IQ Infusion...
DEERFIELD, Ill. Baxter International Inc. (NYSE:BAX), a leader in innovative technology for medication delivery, today announced the CE marking of the Evo IQ Infusion System. In addition to the...
View ArticleClik here to view.
Clover Biopharmaceuticals Initiates Phase I Study of Etanercept Biosimilar...
CHENGDU, China Clover Biopharmaceuticals, a biotechnology company focused on developing novel and transformative biologic therapies, today announced that the first patient was dosed in a Phase I...
View ArticleClik here to view.
三叶草生物制药在中国开展的依那西普生物类似药SCB-808 I期临床试验入组首例受试者
成都 三叶草生物制药，一家致力于创新及变革性生物制药研发的生物制药公司，今天宣布在中国进行的SCB-808 I期临床试验入组首例受试者。该药物是一种预充填小容量注射液Enbrel®（依那西普）的生物类似药，用于治疗类风湿性关节炎和其他自身免疫性疾病。...
View ArticleClik here to view.
Shionogi Announces FDA Approval of Mulpleta® (Lusutrombopag)
OSAKA, Japan & FLORHAM PARK, N.J. Shionogi & Co., Ltd. (hereafter “Shionogi”) announced today that, after completing a Priority Review, the U.S. Food and Drug Administration (FDA) has...
View Article